Revisiting 5α-reductase inhibitors and the risk of prostate cancer

Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9.

Abstract

The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.

Publication types

  • Review

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use*
  • Chemoprevention / methods*
  • Humans
  • Male
  • Neoplasm Staging*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / prevention & control*
  • Risk Factors

Substances

  • 5-alpha Reductase Inhibitors